Vaxcyte Announces $1 Billion Fill-Finish Manufacturing Agreement with Thermo Fisher in North Carolina

Reuters

Sep 30

Vaxcyte Announces $1 Billion Fill-Finish Manufacturing Agreement with Thermo Fisher in North Carolina

Vaxcyte Inc., a clinical-stage vaccine innovation company, has announced a new agreement with Thermo Fisher Scientific to expand domestic fill-finish manufacturing capacity for its broad-spectrum pneumococcal conjugate vaccine candidates. Under the agreement, Thermo Fisher will provide custom commercial fill-finish services at its Greenville, North Carolina facility. The initiative is part of Vaxcyte's long-term U.S. commercial supply strategy and represents up to $1 billion in manufacturing and related services. The expanded capacity is intended to support the future commercial manufacturing of Vaxcyte's vaccines and strengthen the company's domestic supply chain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9537277-en) on September 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571347288"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571347288\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571347288?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571347288","market":"nz","top_or_hot":-1,"title":"Vaxcyte Announces $1 Billion Fill-Finish Manufacturing Agreement with Thermo Fisher in North Carolina","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte Announces $1 Billion Fill-Finish Manufacturing Agreement with Thermo Fisher in North Carolina\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxcyte Inc., a clinical-stage vaccine innovation company, has announced a new agreement with Thermo Fisher Scientific to expand domestic fill-finish manufacturing capacity for its broad-spectrum pneumococcal conjugate vaccine candidates. Under the agreement, Thermo Fisher will provide custom commercial fill-finish services at its Greenville, North Carolina facility. The initiative is part of Vaxcyte's long-term U.S. commercial supply strategy and represents up to $1 billion in manufacturing and related services. The expanded capacity is intended to support the future commercial manufacturing of Vaxcyte's vaccines and strengthen the company's domestic supply chain.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9537277-en) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte Announces $1 Billion Fill-Finish Manufacturing Agreement with Thermo Fisher in North Carolina</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte Announces $1 Billion Fill-Finish Manufacturing Agreement with Thermo Fisher in North Carolina\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte Announces $1 Billion Fill-Finish Manufacturing Agreement with Thermo Fisher in North Carolina\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxcyte Inc., a clinical-stage vaccine innovation company, has announced a new agreement with Thermo Fisher Scientific to expand domestic fill-finish manufacturing capacity for its broad-spectrum pneumococcal conjugate vaccine candidates. Under the agreement, Thermo Fisher will provide custom commercial fill-finish services at its Greenville, North Carolina facility. The initiative is part of Vaxcyte's long-term U.S. commercial supply strategy and represents up to $1 billion in manufacturing and related services. The expanded capacity is intended to support the future commercial manufacturing of Vaxcyte's vaccines and strengthen the company's domestic supply chain.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9537277-en) on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1720051017.SGD","symbol_name":"Allianz Global Artificial Intelligence AT Acc H2-SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL1NsBQh:1","article_id":"2571347288","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571347288","pubTimestamp":1759235413,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vaxcyte Inc., a clinical-stage vaccine innovation company, has announced a new agreement with Thermo Fisher Scientific to expand domestic fill-finish manufacturing capacity for its broad-spectrum pneumococcal conjugate vaccine candidates. Under the agreement, Thermo Fisher will provide custom commercial fill-finish services at its Greenville, North Carolina facility. The initiative is part of Vaxcyte's long-term U.S. commercial supply strategy and represents up to $1 billion in manufacturing and related services. The expanded capacity is intended to support the future commercial manufacturing of Vaxcyte's vaccines and strengthen the company's domestic supply chain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1548497426.USD":"安联环球人工智能AT Acc","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","BK4588":"碎股","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","LU1803068623.USD":"TEMPLETON GLOBAL CLIMATE CHANGE \"AH1\" (USDHDG) ACC","LU0342679015.USD":"ALLIANZ GLOBAL EQUITY UNCONSTRAINED \"AT\" (USD) ACC","BK4112":"金融交易所和数据","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","PCVX":"Vaxcyte, Inc.","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2125909916.SGD":"Natixis Thematics Safety R/A SGD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","NDAQ":"纳斯达克OMX交易所","LU1923622291.USD":"Natixis Thematics Safety R/A USD","TMO":"赛默飞世尔","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU2764263039.SGD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (SGDHDG) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU2063271972.USD":"富兰克林创新领域基金","BK4585":"ETF&股票定投概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2360108059.USD":"BGF CIRCULAR ECONOMY \"A4\" (USD) INC","LU1923621640.USD":"Natixis Thematics Water R/A USD","BK4566":"资本集团","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU0061474960.USD":"天利环球焦点基金AU Acc","LU0557290698.USD":"施罗德环球可持续增长基金","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD"},"translate_title":"Vaxcyte宣布与Thermo Fisher在北卡罗来纳州签订价值10亿美元的灌装制造协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PCVX":0.9,"TMO":0.9},"content_text":"Vaxcyte Announces $1 Billion Fill-Finish Manufacturing Agreement with Thermo Fisher in North Carolina\n    \n\n        Vaxcyte Inc., a clinical-stage vaccine innovation company, has announced a new agreement with Thermo Fisher Scientific to expand domestic fill-finish manufacturing capacity for its broad-spectrum pneumococcal conjugate vaccine candidates. Under the agreement, Thermo Fisher will provide custom commercial fill-finish services at its Greenville, North Carolina facility. The initiative is part of Vaxcyte's long-term U.S. commercial supply strategy and represents up to $1 billion in manufacturing and related services. The expanded capacity is intended to support the future commercial manufacturing of Vaxcyte's vaccines and strengthen the company's domestic supply chain.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9537277-en) on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}